Clinical Trial Update: BIP CVC Clinical Safety and Performance Study [Phase 4]

View source ↗

Summary

Phase 4 safety and performance study of BIP CVC by Bactiguard AB has completed. The trial evaluated safety and effectiveness in preventing central line-associat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Line-associated Bloodstream Infection

Drugs mentioned

• BIP CVC

Snippet

Sponsor: Bactiguard AB | Conditions: Surgery, Central Line Associated Blood Stream Infections (CLABSI) | Phase 4 | Status: COMPLETED